The relation of serum nesfatin-1 level with metabolic and clinical parameters in obese and healthy children

Pediatric Diabetes

Volumn 14, Issue 3, 2013, Pages 189-195

  Abaci, Ayhan ^a   Catli, Gonul ^a   Anik, Ahmet ^a   Kume, Tuncay ^a   Bober, Ece ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Childhood; Insulin resistance; Nesfatin 1; Obesity

Indexed keywords

GLUCOSE; INSULIN; NESFATIN 1; NEUROPEPTIDE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTICLE; BODY MASS; CHILD; CHILDHOOD OBESITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHOOL CHILD;

ADOLESCENT; BLOOD GLUCOSE; BODY MASS INDEX; CALCIUM-BINDING PROTEINS; CHILD; DNA-BINDING PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN; INSULIN RESISTANCE; LIPIDS; MALE; NERVE TISSUE PROTEINS; OBESITY; TURKEY;

EID: 84876813584     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/pedi.12009     Document Type: Article

References (41)

1. Daniels SR, Arnett DK, Eckel RH et al. Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment. Circulation 2005: 111: 1999-2012.
2. Tan BK, Hallschmid M, Kern W, Lehnert H, Randeva HS. Decreased cerebrospinal fluid/plasma ratio of the novel satiety molecule, nesfatin-1/NUCB-2, in obese humans: evidence of nesfatin-1/NUCB-2 resistance and implications for obesity treatment. J Clin Endocrinol Metab 2011: 96: E669-E673.
3. Wren AM, Bloom SR. Gut hormones and appetite control. Gastroenterology 2007: 132: 2116-2130.
4. Simpson K, Parker J, Plumer J, Bloom S. CCK, PYY and PP: the control of energy balance. Handb Exp Pharmacol 2012: 209: 209-230.
5. Oh I, Shimizu H, Satoh T et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006: 443: 709-712.
6. Ramanjaneya M, Chen J, Brown JE et al. Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity. Endocrinology 2010: 151: 3169-3180.
7. Stengel A, Goebel M, Yakubov I et al. Identification and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa. Endocrinology 2009: 150: 232-238.
8. Konczol K, Pinter O, Ferenczi S et al. Nesfatin-1 exerts long-term effect on food intake and body temperature. Int J Obes (Lond) 2012. doi:10.1038/ijo.2012.2.
9. Osaki A, Shimizu H, Ishizuka N, Suzuki Y, Mori M, Inoue S. Enhanced expression of nesfatin/nucleobindin-2 in white adipose tissue of ventromedial hypothalamus-lesioned rats. Neurosci Lett 2012: 11: 46-51.
10. Price TO, Samson WK, Niehoff ML, Banks WA. Permeability of the blood-brain barrier to a novel satiety molecule nesfatin-1. Peptides 2007: 28: 2372-2381.
11. Kuczmarski RJ, Ogden CL, Guo SS et al. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11 2002: 246: 1-190.
12. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976: 51: 170-179.
13. American Academy of Pediatrics. National Cholesterol Education Program: report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics 1992: 89: 525-584.
14. Genuth S, Alberti KG, Bennett P et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003: 26: 3160-3167.
15. Rosner B, Prineas RJ, Loggie JM, Daniels SR. Blood pressure nomograms for children and adolescents, by height, sex, and age, in the United States. J Pediatr 1993: 123: 871-886.
16. Sclafani A. Gut-brain nutrient signaling. Appetition vs. satiation. Appetite 2012. doi:10.1016/j.appet.2012.05.024.
17. Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008: 93: S64-S73.
18. Woods SC. The control of food intake: behavioral versus molecular perspectives. Cell Metab 2009: 9: 489-498.
19. Benoit SC, Clegg DJ, Seeley RJ, Woods SC. Insulin and leptin as adiposity signals. Recent Prog Horm Res 2004: 59: 267-285.
20. Zegers D, Beckers S, Mertens IL, Van Gaal LF, Van HW. Association between polymorphisms of the Nesfatin gene, NUCB2, and obesity in men. Mol Genet Metab 2011: 103: 282-286.
21. Aydin S, Dag E, Ozkan Y et al. Nesfatin-1 and ghrelin levels in serum and saliva of epileptic patients: hormonal changes can have a major effect on seizure disorders. Mol Cell Biochem 2009: 328 (1-2): 49-56.
22. Li QC, Wang HY, Chen X, Guan HZ, Jiang ZY. Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans. Regul Pept 2010: 159 (1-3): 72-77.
23. Tsuchiya T, Shimizu H, Yamada M et al. Fasting concentrations of nesfatin-1 are negatively correlated with body mass index in non-obese males. Clin Endocrinol (Oxf) 2010: 73: 484-490.
24. Saldanha JF, Carrero JJ, Lobo JC et al. The newly identified anorexigenic adipokine nesfatin-1 in hemodialysis patients: Are there associations with food intake, body composition and inflammation? Regul Pept 2012: 173: 82-85.
25. Hedblad B, Nilsson P, Janzon L, Berglund G. Relation between insulin resistance and carotid intima-media thickness and stenosis in nondiabetic subjects. Results from a cross-sectional study in Malmo, Sweden. Diabet Med 2000: 17: 299-307.
26. Pozzan R, Pozzan R, Brandão AA, Magalhães MEC, Brandão AP. Níveis de insulina e HOMA em uma amostra da cidade do Rio de Janeiro. Estudo do Rio de Janeiro. Rev Socerj 2003: 16: 75.
27. Ghiringhello MT, Vieira JG, Tachibana TT et al. Distribution of HOMA-IR in Brazilian subjects with different body mass indexes. Arq Bras Endocrinol Metab 2006: 50: 573-574.
28. Geloneze B, Repetto EM, Geloneze SR, Tambascia MA, Ermetice MN. The threshold value for insulin resistance (HOMA-IR) in an admixtured population IR in the Brazilian Metabolic Syndrome Study. Diabetes Res Clin Pract 2006: 72: 219-220.
29. Esteghamati A, Ashraf H, Esteghamati AR et al. Optimal threshold of homeostasis model assessment for insulin resistance in an Iranian population: the implication of metabolic syndrome to detect insulin resistance. Diabetes Res Clin Pract 2009: 84: 279-287.
30. Lee S, Choi S, Kim HJ et al. Cutoff values of surrogate measures of insulin resistance for metabolic syndrome in Korean non-diabetic adults. J Korean Med Sci 2006: 21: 695-700.
31. Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care 2000: 23: 171-175.
32. Bonora E, Kiechl S, Willeit J et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998: 47: 1643-1649.
33. Nakai Y, Fukushima M, Nakaishi S et al. The threshold value for insulin resistance on homeostasis model assessment of insulin sensitivity. Diabet Med 2002: 19: 344-348.
34. Tresaco B, Bueno G, Pineda I, Moreno LA, Garagorri JM, Bueno M. Homeostatic Model Assessment (HOMA) index cut-off values to identify the metabolic syndrome in children. J Physiol Biochem 2005: 61: 381-388.
35. Acosta B, Escalona MO, Maiz AG, Pollak FC, Leighton FP. Determinación del índice de resistencia insulínica mediante HOMA en una población de la región metropolitana de Chile. Rev Med Chile 2002: 130: 1227-1231.
36. Keskin M, Kurtoglu S, Kendirci M, Atabek ME, Yazici C. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 2005: 115: 500-503.
37. Rocco ER, Mory DB, Bergamin CS et al. Optimal cutoff points for body mass index, waist circumference and HOMA-IR to identify a cluster of cardiometabolic abnormalities in normal glucose-tolerant Brazilian children and adolescents. Arq Bras Endocrinol Metabol 2011: 55: 638-645.
38. Su Y, Zhang J, Tang Y, Bi F, Liu JN. The novel function of nesfatin-1: anti-hyperglycemia. Biochem Biophys Res Commun 2010: 391: 1039-1042.
39. Gonzalez R, Reingold BK, Gao X, Gaidhu MP, Tsushima RG, Unniappan S. Nesfatin-1 exerts a direct, glucose-dependent insulin tropic action on mouse islet beta- and MIN6 cells. J Endocrinol 2011: 208: R9-R16.
40. Stengel A, Tache Y. Mini review: nesfatin-1--an emerging new player in the brain-gut, endocrine, and metabolic axis. Endocrinology 2011: 152: 4033-4038.
41. Zhang Z, Li L, Yang M, Liu H, Boden G, Yang G. Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2012: 120: 91-95.